Clinical Trial Update: REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection [Phase 2]

View source ↗

Summary

Phase 2 trial update for REP 2139-Ca combined with Pegasys in chronic hepatitis B with HBeAg-negative status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• REP 2139-Ca (REP 2139-Ca)

Snippet

Sponsor: Replicor Inc. | Conditions: Chronic HBV Infection (HBeAg Negative) | Phase 2 | Status: COMPLETED